SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial

Shares of Sellas Life Sciences (SLS) slipped 1% overnight heading into Thursday ahead of a pancreatic cancer conference where the company will present three early-stage studies of its second cancer drug, SLS009. The treatment is already being tested in patients with a form of blood cancer, and reta…